Clinical Trial Update: Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) [Phase 1, Phase 2]

View source ↗

Summary

Umbrella trial MK-3475-06E (KEYMAKER-U06) is evaluating pembrolizumab-based combination therapies for Esophageal Squamous Cell Carcinoma and is currently in Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING